Novyra Pharmachem Limited (formerly known as Bansisons Tea Industries Limited) has announced another revision to its board meeting schedule for the consideration of quarterly financial results. The company has now postponed its board meeting to April 29, 2026, marking the second rescheduling for the same agenda.

Latest Meeting Schedule Changes

The company initially scheduled the board meeting for April 18, 2026, which was first postponed to April 25, 2026. In the latest communication dated April 25, 2026, the company has further rescheduled the meeting to April 29, 2026.

Board Meeting Agenda

The rescheduled board meeting will address several key agenda items related to the company's financial performance for the fourth quarter of fiscal year 2026. The primary agenda includes:

• Consideration and approval of audited financial results for Q4FY26
• Review of auditor's report for the quarter and year ended March 31, 2026
• Certificate for unmodified opinion from auditors
• Other business matters as deemed necessary

Regulatory Compliance

The latest meeting revision has been communicated to BSE Limited in accordance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal communication was signed by Director Anilkumar Mohanbhai Amreliya (DIN: 11339148) on behalf of the company.

Company Background

Novyra Pharmachem Limited, formerly known as Bansisons Tea Industries Limited, operates from its registered office at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, Vasta Devdi Road, Surat, Gujarat. The company continues its business operations under the new name while maintaining compliance with all regulatory requirements and disclosure obligations.

Novyra Pharmachem Limited , formerly known as Bansisons Tea Industries Limited, has submitted its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The company also maintains its scheduled board meeting for April 18, 2026, to consider Q4FY26 and FY26 audited financial results.

Regulatory Compliance Certificate

On April 10, 2026, Novyra Pharmachem Limited filed the mandatory certificate with BSE Limited, confirming compliance with dematerialization requirements for Q4FY26. The certificate was signed by Director Anilkumar Mohanbhai Amreliya (DIN: 11339148) and submitted to BSE under scrip code 519353.

Registrar Confirmation

S.K. Infosolutions Pvt. Limited, the company's registrar and transfer agent, provided confirmation on April 04, 2026, regarding the dematerialization process. The registrar confirmed that securities received from depository participants during Q4FY26 were properly processed and that security certificates were mutilated and cancelled after due verification.

Upcoming Board Meeting

The company maintains its previously announced board meeting scheduled for April 18, 2026, at the registered office in Surat, Gujarat. The meeting will address audited financial results for Q4FY26 and FY26, along with the auditor's report pursuant to SEBI LODR Regulation 33.

Trading Window Status

In compliance with insider trading regulations, the trading window remains closed from April 01, 2026, and will reopen 48 hours after the declaration of financial results. This restriction applies to all designated persons under the company's Code of Fair Disclosure.

Company Information

Novyra Pharmachem Limited operates under CIN L21001GJ1987PLC171085 with its registered office at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, Surat, Gujarat. The company maintains regulatory compliance through its registrar S.K. Infosolutions Pvt. Limited, located in Kolkata.